Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCILI: ASCT01 in Critical Limb Ischemia
2010-024391-25Phase 2Terminated
- Sponsor
- XCell-Center
- Start
- Dec 2010
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic limb-threatening ischemia (CLTI) comparing ASCT01 with Placebo (2 arms). Primary endpoint: Major amputation or persistent critical limb ischemia at 3 months. Started Dec 2010; status: terminated.
02
Drugs
ASCT 01
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2010-024391-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024391-25.